ID: ALA2086887

Max Phase: Preclinical

Molecular Formula: C32H30N6O4S

Molecular Weight: 594.70

Molecule Type: Small molecule

Representations

Canonical SMILES:  NCc1ccc(CNC(=O)c2cccc(-c3noc(CN(Cc4ccccn4)S(=O)(=O)/C=C/c4ccccc4)n3)c2)cc1

Standard InChI:  InChI=1S/C32H30N6O4S/c33-20-25-12-14-26(15-13-25)21-35-32(39)28-10-6-9-27(19-28)31-36-30(42-37-31)23-38(22-29-11-4-5-17-34-29)43(40,41)18-16-24-7-2-1-3-8-24/h1-19H,20-23,33H2,(H,35,39)/b18-16+

Standard InChI Key:  GMOOKVYVSFHEAB-FBMGVBCBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 594.70

Molecular Weight (Monoisotopic): 594.2049

AlogP: 4.52

#Rotatable Bonds: 12

Polar Surface Area: 144.31

Molecular Species: BASE

HBA: 8

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 9.28

CX LogP: 4.11

CX LogD: 2.24

Aromatic Rings: 5

Heavy Atoms: 43

QED Weighted: 0.21

Np Likeness Score: -1.68

References

1. Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I, Courtney SM, Brookfield FA, Yarnold CJ, Marston RW, Johnson PD, Johnsen SF, Palfrey JJ, Vaidya D, Erfan S, Ichihara O, Felicetti B, Palan S, Pedret-Dunn A, Schaertl S, Sternberger I, Ebneth A, Scheel A, Winkler D, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Dominguez C, Wityak J..  (2012)  Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.,  55  (3): [PMID:22224594] [10.1021/jm201310y]

Source

Source(1):

• Scientific Literature